Haematopoietic Stem Cell Transplant for Norovirus-Induced Intestinal Failure in X-linked Agammaglobulinemia

Abstract excerpt

Since the first clinical description in 1952, immunoglobulin replacement therapy remains the mainstay of treatment of patients with X-linked agammaglobulinemia (XLA). However, this therapy only replaces IgG isotype and does not compensate for the loss of Bruton tyrosine kinase in non-B-lymphocytes. Patients may still therefore develop complications despite current standard of care. Here, we describe an XLA...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal disorders and treatments
• Share to Immunodeficiency and Autoimmune Disorders
• Share to Viral gastroenteritis research and epidemiology